

## II. Claim Amendments

Claim 1 (Cancelled, without prejudice or disclaimer)

2. (Previously Amended) A peptide consisting of 16 to 55 amino acid residues, comprising the amino acid sequence YKLVCYYTWSQYREG (SEQ ID NO: 1).

Claims 3-6 (Cancelled, without prejudice or disclaimer)

7. (Previously Amended) A pharmaceutical composition comprising a peptide according to claim 2, and a pharmaceutically acceptable carrier.

Claims 8-10 (Cancelled without prejudice or disclaimer)

11. (Previously Amended) A test kit for use in the detection of activated autoreactive T cells, comprising a peptide according to claim 2.

Claim 12 (Cancelled, without prejudice or disclaimer)

13. (Previously Amended) A pharmaceutical composition consisting of one or more peptides selected from the group consisting of peptides consisting of 16 to 55 amino acid residues and comprising the amino acid sequence YKLVCYYTWSQYREG (SEQ ID NO:1).

14. (Cancelled, without prejudice or disclaimer).

15. (Currently Amended) A method of inducing systemic immunological tolerance, comprising administering mucosally to a patient in need thereof a pharmaceutical

composition comprising one or more peptides containing 16 to 55 amino acid residues selected from the group consisting of the amino acid sequence LVCYYTSWS (SEQ ID NO:60) and a pharmaceutically acceptable carrier.

16. (Original) A method for inducing a systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition according to claim 13.
17. (Cancelled without prejudice or disclaimer)